The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer.

Twenty-one patients with histologically proven advanced or disseminated non-small cell lung cancer were treated with cisplatinum 80 mg/m2 i.v. day 1 and etoposide (VP16) 80 mg/m2 i.v. day 1- greater than 3.15 patients were evaluable for response. One patient (6.6%) achieved a complete response, 4 (26.7%) a partial response and 6 (40.0%) a stabilization of disease. Four patients (26.7%) progressed. An improvement in performance status was obtained in more than 50% of cases. Responders had a mean survival of 345 + days, while non-responders 191.7 days. The treatment was generally well tolerated. In our opinion this combination regimen offers good palliation for patients affected by advanced and/or metastatic non-small cell lung cancer.

[1]  J. Mulshine,et al.  Treatment of non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  T. Miller,et al.  Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study. , 1986, Cancer treatment reports.

[3]  M. Kris,et al.  Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. , 1986, Cancer treatment reports.

[4]  A. Ardizzoni,et al.  Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. , 1986, Cancer treatment reports.

[5]  J. Sculier,et al.  Chemotherapy of non-small-cell lung cancer. , 1985, Seminars in oncology.

[6]  M. Cullen,et al.  Cisplatin, etoposide, and radiotherapy in regional inoperable squamous cell carcinoma of the bronchus. , 1985, Seminars in oncology.

[7]  J. Klastersky.  VP-16 and cisplatin in the treatment of non-small-cell lung cancer. , 1985, Seminars in oncology.

[8]  V. Diehl,et al.  cis-Platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial. , 1984, European journal of cancer & clinical oncology.

[9]  F. Nozzoli,et al.  Cisplatin and etoposide combination in the treatment of bronchogenic carcinoma. , 1984, Chemioterapia : international journal of the Mediterranean Society of Chemotherapy.

[10]  F. Muggia,et al.  Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies. , 1984, International journal of radiation oncology, biology, physics.

[11]  C. Coltman,et al.  Evaluation of single-agent cisplatin in the management of non-small cell carcinoma of the lung: a Southwest Oncology Group Study. , 1983, Cancer treatment reports.

[12]  J. Klastersky,et al.  Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC lung cancer working party (Belgium) , 1982, Cancer.

[13]  H. Schmoll.  Review of etoposide single-agent activity. , 1982, Cancer treatment reviews.

[14]  N. Martini,et al.  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. , 1981, Annals of internal medicine.

[15]  A. Goldhirsch,et al.  Cis-dichlorodiammineplatinum (II) and VP 16-213 combination chemotherapy for non-small cell lung cancer. , 1981, Medical and pediatric oncology.

[16]  A. Teirstein,et al.  MACC (methotrexate, adriamycin, cyclophosphamide and CCNU) in advanced lung cancer , 1979, Cancer.

[17]  P. Woolley,et al.  5‐fluorouracil, adriamycin, and mitomycin‐C (FAM) chemotherapy for adenocarcinoma of the lung , 1979, Cancer.

[18]  R. Livingston,et al.  Comparative trial of combination chemotherapy in extensive squamous carcinoma of the lung: a Southwest Oncology Group Study. , 1977, Cancer treatment reports.